{"slideshow_credits": null, "snippet": "Amgen\u2019s deal to buy Onyx Pharmaceuticals shows the value of having a tough negotiator at the helm, the author writes.", "abstract": "Amgen\u2019s deal to buy Onyx Pharmaceuticals shows the value of having a tough negotiator at the helm, the author writes.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Rob", "role": "reported", "lastname": "COX", "rank": 1, "organization": ""}], "original": "By ROB COX"}, "web_url": "http://dealbook.nytimes.com/2013/09/05/amgen-investors-gain-from-having-an-ex-investment-banker-as-c-e-o/", "lead_paragraph": null, "headline": {"main": "Amgen Investors Gain From Having an Ex-Investment Banker as C.E.O.", "kicker": "DealBook"}, "_id": "5228b26b38f0d8740ac9de4d", "word_count": "420", "multimedia": [], "pub_date": "2013-09-05T12:28:25Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "persons", "value": "Bradway, Robert A", "rank": "1"}, {"name": "organizations", "value": "Amgen Inc", "rank": "1"}, {"name": "organizations", "value": "Onyx Pharmaceuticals", "rank": "2"}, {"name": "subject", "value": "Biotechnology", "rank": "1"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "2"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}